Skip to main content
Equibles
DNA logo

DNA · Ginkgo Bioworks Holdings, Inc.

Track DNA — free

Use DNA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DNA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.79 -0.45 (-6.22%) At close · Aug 14
Market Cap
$457.24M
Shares
67.34M

Ginkgo Bioworks Holdings, Inc. Earnings Call Transcripts

Every quarterly earnings call for Ginkgo Bioworks Holdings, Inc. (DNA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼14.4% $66.40M −$670.13M '22 Q3 22-11-14 ▼33.8% $98.28M −$175.47M '22 Q4 23-01-11 ▼52.1% $80.70M −$204.97M '23 Q1 23-05-10 ▼44.3% $80.57M −$173.31M '23 Q2 23-08-09 ▼16.5% $55.43M −$302.89M '23 Q3 23-11-08 ▼64.6% $34.76M −$211.69M '23 Q4 24-02-29 ▼53% $37.94M −$165.91M '24 Q1 24-05-09 ▼30.2% $56.21M −$217.18M '24 Q2 24-06-30 ▲60.6% $89.05M −$56.40M '24 Q3 24-11-12 ▲26.2% $43.85M −$107.53M '24 Q4 25-02-25 ▲0.8% $38.23M −$90.96M '25 Q1 25-05-06 ▼30.4% $39.13M −$60.30M '25 Q2 25-08-07 ▼56.4% $38.84M −$80.75M '25 Q3 25-11-06 ▲23.1% $53.95M −$80.75M '25 Q4 26-02-26 ▼49.1% $19.47M −$82.59M '26 Q1 26-05-07 LATEST ▼48.5% $20.16M −$46.71M '26 Q2 26-08-05
Earnings call
FY26 · Q2
2026-08-05
Earnings conference call (announced in 8-K)
Positive tone Nebula lab in Boston NSF-funded university labs announcement Autonomous labs as national imperative
Revenue
$20.16M
▼ 48.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Ginkgo Bioworks Holdings, Inc. Q1 FY2026 Earnings Call
Positive tone Autonomous labs / Nebula strategy AI, robotics & software investment Financial performance
Revenue
$19.47M
▼ 49.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Ginkgo Bioworks Holdings, Inc. Q4 FY2025 Earnings Call
Positive tone Cell Engineering Revenue Decline Autonomous Labs Strategy Cost Restructuring & Cash Burn
Revenue
$53.95M*
▲ 23.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-15
Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-06
Ginkgo Bioworks Holdings, Inc. Q3 FY2025 Earnings Call
Positive tone Tools business and robotics Biosecurity business AI and biology transformation
Revenue
$38.84M
▼ 56.4% YoY
Diluted EPS
$-1.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ginkgo Bioworks Holdings, Inc. Q2 FY2025 Earnings Call
Positive tone Cost restructuring and EBITDA breakeven target Biosecurity business and guidance reduction Transition to life science tools business
Revenue
$39.13M
▼ 30.4% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ginkgo Bioworks Holdings, Inc. Q1 FY2025 Earnings Call
Positive tone Government and Biosecurity opportunities Cell Engineering revenue growth Cost reduction and path to EBITDA breakeven
Revenue
$38.23M
▲ 0.8% YoY
Diluted EPS
$-1.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Ginkgo Bioworks Holdings, Inc. Q4 FY2024 Earnings Call
Positive tone Cell engineering revenue growth Tools and Data Points offerings Adjusted EBITDA break-even and cost cuts
Revenue
$43.85M*
▲ 26.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Ginkgo Bioworks Holdings, Inc. Q3 FY2024 Earnings Call
Positive tone Cell engineering revenue / customer mix Cost cutting / path to adjusted EBITDA breakeven AI platform / model offerings
Revenue
$89.05M
▲ 60.6% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Ginkgo Bioworks Holdings, Inc. Q2 FY2024 Earnings Call
Cautious tone Tools and platform democratization Cost reduction and path to EBITDA breakeven Biosecurity business
Revenue
$56.21M
▼ 30.2% YoY
Diluted EPS
$-4.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Ginkgo Bioworks Holdings, Inc. Q1 FY2024 Earnings Call
Positive tone RAC automation platform and Biofab1 consolidation Downstream value share and guidance withdrawal Path to adjusted EBITDA breakeven
Revenue
$37.94M
▼ 53% YoY
Diluted EPS
$-3.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Ginkgo Bioworks Holdings, Inc. Q4 FY2023 Earnings Call
Positive tone Biopharma customer wins Cell Engineering program growth Biosecurity business
Revenue
$34.76M*
▼ 64.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Ginkgo Bioworks Holdings, Inc. Q3 FY2023 Earnings Call
Revenue
$55.43M
▼ 16.5% YoY
Diluted EPS
$-6.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Ginkgo Bioworks Holdings, Inc. Q2 FY2023 Earnings Call
Revenue
$80.57M
▼ 44.3% YoY
Diluted EPS
$-3.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Ginkgo Bioworks Holdings, Inc. Q1 FY2023 Earnings Call
Revenue
$80.70M
▼ 52.1% YoY
Diluted EPS
$-4.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-11
Ginkgo Bioworks Holdings, Inc. Q4 FY2022 Earnings Call
Revenue
$98.28M*
▼ 33.8% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Ginkgo Bioworks Holdings, Inc. Q3 FY2022 Earnings Call
Revenue
$66.40M
▼ 14.4% YoY
Diluted EPS
$-16.40
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Ginkgo Bioworks Holdings, Inc. Q2 FY2022 Earnings Call
Revenue
$144.62M
▲ 231.4% YoY
Diluted EPS
$-16.40
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Ginkgo Bioworks Holdings, Inc. Q1 FY2022 Earnings Call
Revenue
$168.41M
▲ 281.9% YoY
Diluted EPS
$-14.80
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-12
Ginkgo Bioworks Holdings, Inc. Q4 FY2021 Earnings Call
Revenue
$148.49M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Ginkgo Bioworks Holdings, Inc. Q3 FY2021 Earnings Call
Revenue
$77.61M
▲ 483.4% YoY
Diluted EPS
$-3.20
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Ginkgo Bioworks Holdings, Inc. Q1 FY2021 Earnings Call
Revenue
$44.10M
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts CIK 1830214 CUSIP 37611X209 13F (30d) 184 filings 174 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)